弥漫大B细胞淋巴瘤治疗新进展ppt课件.pptVIP

Cunningham D, et al. ASCO 2009. Abstract 8506. *249 patients not evaluable or data missing. R-CHOP-14 vs R-CHOP-21 in Newly Diagnosed DLBCL: Responses LNH03-6B GELA:  R-CHOP-14 vs R-CHOP-21  in Elderly DLBCL Patients Primary endpoint: EFS Secondary endpoints: CR or CRu, ORR, PFS , DFS, OS, dose intensity, toxicity Delarue R, et al. ASH 2009. Abstract 406. R-CHOP every 14 days for 8 cycles + IT MTX for 4 cycles (n = 103) R-CHOP every 21 days for 8 cycles + IT MTX for 4 cycles (n = 99) DLBCL patients60-80 yrs of age (N = 202) ProphylacticDarbepoetin alfa Conventio